ACADIA Pharmaceuticals Volcan Bond
ACAD Stock | USD 16.29 0.08 0.49% |
ACADIA Pharmaceuticals holds a debt-to-equity ratio of 0.146. At present, ACADIA Pharmaceuticals' Short Term Debt is projected to increase significantly based on the last few years of reporting. The current year's Net Debt To EBITDA is expected to grow to 2.03, whereas Debt To Equity is forecasted to decline to 0.11. . ACADIA Pharmaceuticals' financial risk is the risk to ACADIA Pharmaceuticals stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
ACADIA Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. ACADIA Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps ACADIA Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect ACADIA Pharmaceuticals' stakeholders.
For most companies, including ACADIA Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for ACADIA Pharmaceuticals, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, ACADIA Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 4.6731 | Book Value 3.47 | Operating Margin 0.1264 | Profit Margin 0.1383 | Return On Assets 0.0872 |
ACADIA |
Given the importance of ACADIA Pharmaceuticals' capital structure, the first step in the capital decision process is for the management of ACADIA Pharmaceuticals to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of ACADIA Pharmaceuticals to issue bonds at a reasonable cost.
Popular Name | ACADIA Pharmaceuticals Volcan Compania Minera |
Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
Equity ISIN Code | US0042251084 |
Bond Issue ISIN Code | USP98047AC08 |
S&P Rating | Others |
Maturity Date | 11th of February 2026 |
Issuance Date | 11th of February 2021 |
Coupon | 4.375 % |
ACADIA Pharmaceuticals Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
International Game Technology | US460599AD57 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
MGM Resorts International | US552953CD18 | Details | |
Valero Energy Partners | US91914JAA07 | Details |
Understaning ACADIA Pharmaceuticals Use of Financial Leverage
ACADIA Pharmaceuticals' financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures ACADIA Pharmaceuticals' total debt position, including all outstanding debt obligations, and compares it with ACADIA Pharmaceuticals' equity. Financial leverage can amplify the potential profits to ACADIA Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if ACADIA Pharmaceuticals is unable to cover its debt costs.
Last Reported | Projected for Next Year | ||
Short and Long Term Debt Total | 57.2 M | 60.1 M | |
Net Debt | -131.5 M | -124.9 M | |
Short Term Debt | 9.4 M | 9.9 M | |
Net Debt To EBITDA | 1.94 | 2.03 | |
Debt To Equity | 0.12 | 0.11 | |
Interest Debt Per Share | 0.05 | 0.04 | |
Debt To Assets | 0.09 | 0.09 | |
Long Term Debt To Capitalization | 0.08 | 0.05 | |
Total Debt To Capitalization | 0.08 | 0.09 | |
Debt Equity Ratio | 0.12 | 0.11 | |
Debt Ratio | 0.09 | 0.09 | |
Cash Flow To Debt Ratio | (2.57) | (2.70) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:Check out the analysis of ACADIA Pharmaceuticals Fundamentals Over Time. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 28.347 | Earnings Share 0.78 | Revenue Per Share 5.622 | Quarterly Revenue Growth 0.183 | Return On Assets 0.0872 |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.